Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study, conducted academic Pilot research purposes, this is not clear as
to permit. when orlistat to sibutramine merge if there are additional effects of BMI and
group, which has an attribute that is greater for the combined effect is to analyze.
- Study phase: Investigator-initiated clinical study (Pilot study)
- Method of blinding: Double-blind
- Control: Placebo-controlled
- Assignment method: Randomization (Sibutramine monotherapy group: Orlistat and
Sibutramine combination group = 1 : 1)
- Studied disease: Obesity
- Study population: Subjects eligible for inclusion/exclusion criteria
- Dosing period: Total 18 weeks Run-in period (2 weeks), dosing period (12 weeks) and
post-dosing observation period (4 weeks)